Amplia Therapeutics is an Australian company developing a kinase inhibitor AMP945 for cancer and fibrosis. Amplia has commenced ACCENT, a Phase 1b/2a clinical trial in first-line advanced pancreatic cancer patients. AMP945 is added to standard regimens of gemcitabine and nab-paclitaxel (NCT05355298). Recruitment is open at sites in Melbourne, Sydney, and Brisbane.